Attention Long-Term Virtu Financial Inc. (NYSE: VIRT) Shareholders: Grabar Law Office Investigates Claims on Your Behalf as SEC and Virtu Reach Tentative Settlement

Attention Long-Term Virtu Financial Inc. (NYSE: VIRT) Shareholders: Grabar Law Office Investigates Claims on Your Behalf as SEC and Virtu Reach Tentative Settlement GlobeNewswire July 02, 2025 PHILADELPHIA, July 02, 2025 (GLOBE NEWSWIRE) — A federal securities fraud class action alleging that Virtu Financial Inc. (NYSE: VIRT), and certain of its officers failed to make […]

Modal and Centerbridge Partners Announce the U.K.’s Largest Industrial Outdoor Storage Portfolio Financing with Apollo

Modal, a London-based investment and management firm specializing in Industrial Outdoor Storage (“IOS”) assets, and Centerbridge Partners, L.P. (“Centerbridge”), a leading global private investment firm, today announced that Apollo-managed credit funds will provide senior financing to their U.K. IOS portfolio. The financing follows Modal's significant expansion over the past 12 months, establishing it as one

Swensons Drive-In “Parks” at TRG

Theregional Ohio drive-in brand taps Dallas-based ad agency to fuel brand expansion Swensons Drive-In, the 91-year-old quick-service brand with a fiercely loyal fanbase and a drive-in experience unlike any other, has named TRG its agency of record. The partnership will focus on brand strategy and creative as Swensons looks to expand its roots. https://mma.prnewswire.com/media/2644929/TRG_Logo.jpg Founded

Cousins Maine Lobster Debuts Winston-Salem Truck

Husband-Wife Duo Rolls Out Third CML Truck in North Carolina Cousins Maine Lobster (CML),the industry-leading fast-casual lobster roll brand, is expanding its North Carolina footprint with the launch of a new food truck in the Piedmont Triad metropolitan region. The husband-and-wife duo Savas and Victoria Alkoc, who have been operators with Cousins Maine Lobster for

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

(NASDAQ:FTRE), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi &

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings GlobeNewswire July 02, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Fortrea between

Silver Just Hit a 13-Year High — and Forecasts Say It Could Triple

USA News GroupNews Commentary Issued on behalf of Magma Silver Corp. USA News GroupNews Commentary – Silver has officially broken through 13-year highs, with prices surging past $36 per ounce- a move some analysts are calling a generational technical breakout. Since January, the metal has climbed from $28.92, triggering a wave of activity as Americans

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health GlobeNewswire July 02, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in

Lynozyfic(TM) (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

(NASDAQ:REGN), TARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic(TM) (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a

Scroll to Top